OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial - Concepedia

Concepedia

Publication | Open Access

OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial

DOI Full Paper Access

53

Citations

1

References

2018

Year

Philip J. Mease, H. Kellner, Akimichi Morita, A. Kivitz, Kim Papp, Stella Aslanyan, Bret Berner, S. Chen, Ann Eldred, Frank Behrens

Annals of the Rheumatic Diseases

References

	Year	Citations

Page 1